Edinburgh IN obstetrics and gynecology the suggested indications for progesterone therapy include arrest of endometrial bleeding, conversion of the endometrium to a secretory phase in persistent proliferative states or in amenorrhaea, premenstrual tension, dysmenorrhoea, threatened or habitual abortion. To accomplish successful results in these conditions several possible modes of action can be postulated. The compound may act directly upon the endometrium affecting the bleeding mechanism or the cytological structure, and these two aspects are not interdependent because bleeding may be associated with any histological state of the endometrium whether normal or abnormal, whether proliferative or secretory. Secondly, there may be a direct action upon the pituitary with inhibition of gonadotrophic secretion. Thirdly, there may be a direct action upon the ovary, and lastly there may be more remote systemic actions affecting the symptoms of such conditions as premenstrual tension in which the underlying oetiological factors have not yet been determined.
There are two methods by which the value of progestational preparations can be assessed-by carefully controlled clinical trials, or by determining the rationale of therapy by scientific research or, more satisfactorily, by a combination of both.
The new progestational compounds can certainly arrest endometrial bleeding by inducing a "medical curettage", but this method seems to have no particular advantage over that in which cestrogens alone are used.
In amenorrhcea progestational compounds may produce secretory changes in an oestrogenprimed endometrium, but this response is not constant and is presumably dependent upon the dosage and the sensitivity of the target organ. However, there seems no advantage in establishing cyclical secretory changes in such cases without evidence that ovarian function is influenced to the extent of inducing a return to normal ovulatory cycles. The conversion of a proliferative to a secretory endometrium in cystic glandular hyperplasia is of limited and temporary value because there is no conclusive evidence that cyclical therapy with progestational agents will lead to ovulatory menstrual cycles.
It has been suggested that in infertility patients progestational compounds may be of value in correcting an inadequate luteal phase of the menstrual cycle. In my experience, evidence of deficient corpus luteum activity is found in 3% of infertility patients, but only as an isolated occurrence. Repeated biopsy in subsequent cycles invariably shows a normal endometrium. Thus, in these cases, there is no real indication for such therapy and, as control is impossible, there can be no proof, not even by a successful pregnancy, that this treatment is of any value.
Being manifest largely by subjective phenomena, premenstrual tension is one of the most difficult conditions in which to assess results of therapy. If an altered cestrogen/progesterone ratio is an etiological factor, there may well be a place for treatment by the progestational agents but it would be reasonable to suppose that added cestrogen or aestrogen conversion should vitiate results. Dysmenorrheea is associated with the same difficulties as premenstrual tension in assessing the results of treatment. The totally unphysiological procedure of suppressing ovulation by these or other drugs is hardly a justifiable means of dealing with this or any other gynwcological condition.
It will be difficult to establish that these compounds play any part in preventing abortion. Animal experiments do not support this contention and masculinizing effects upon the female foetus suggest that more harm than good may sometimes result from their early and longcontinued use.
The use of progestational compounds in clinical practice is confused and the preliminary results of research into their action have done nothing to clarify the position. These agents are having an effect upon the endometrium;-they also suppress ovarian function if given during the menstrual cycle. What is not clear is their mode of action. Broadly speaking these compounds may be divided into two groups-those with, and those without, cestrogenic activity. To date, most research work has been concerned with the former group and it is impossible to assess to what extent their effect is due to the oestrogenic element, particularly in regard to pituitary suppression. Before recommending wide clinical use of these preparations their precise mode of action should be determined. In further research and clinical trials, unnecessary confusion which arises from using preparations known to have cestrogenic activity, either through added cestrogen or cestrogen conversion, should be avoided and, in the first instance, only compounds without an cestrogenic element but of proven progestational activity should be studied.
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